This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Atrisone, dapsone topical gel twice daily (BID)
Description: Aczone, formerly called Atrisone, is a 5% topical dapsone gel that has antibiotic and anti-inflammatory activity. Aczone contains dapsone which is highly lipophilic and previously has only been commercially available as an oral tablet. The Atrix SMP technology provides a platform for highly water-insoluble drugs, such as dapsone, to be delivered topically, right at the site of disease.
Fujisawa Healthcare Inc, the North American subsidiary of Fujisawa Pharmaceutical Co., Ltd., has licensed the marketing rights to Atrix Laboratories, Inc for Atrisone for the treatment of acne and is providing significant support for the development of the product.
QLT and Astellas
In July 2005, QLT announced that by mutual agreement it will acquire all rights to Aczone gel, ending its Collaboration, Licensing and Supply Agreement partnership with Astellas.
Through an agreement entered into today with Astellas, QLT USA, Inc., a wholly owned subsidiary of QLT, acquires full marketing rights to Aczone gel in the United States, Canada and Mexico from Astellas US LLC. As a result of this transaction, QLT now owns worldwide rights to Aczone.
QLT and Allergan
In June 2008, Allergan announced that its wholly-owned subsidiary, Allergan Sales, LLC, entered into an agreement with QLT USA, a wholly-owned subsidiary of QLT, to acquire QLT's Aczone...See full deal structure in Biomedtracker
Pink Sheet Atrix/Fujisawa submit Aczone
Additional information available to subscribers only: